High-risk HPV Prevalence Estimates Among Older Patients: Implications for Cervical Cancer Screening Programs

Overview

Journal Indian J Community Med

Date 2024 Sep 18

PMID 39291120

Authors

Sneha Mittal

Yamini Kansal

Bhumika Singh

Vineeta Gupta

Affiliations

Soon will be listed here.

Abstract

Background: Due to the heterogeneity of existing studies and wide range of human papilloma virus (HPV) prevalence in India, further research into the incidence of HR-HPV and its spectrum of genotypes is essential to develop screening policies. This study aimed to determine the incidence and demographic distribution of HR-HPV among cisgender female patients attending a tertiary care facility in North India.

Materials And Methods: This study was conducted in the Department of Obstetrics and Gynaecology, SGRR Institute of Medical and Health Sciences, Dehradun, India. HPV-DNA test results of 653 female patients were assessed for HR-HPV positivity, genotyping, and age-based differences via Chi-square analysis.

Results: Overall prevalence of HR-HPV was 4.90%, HPV-16 was 1.37%, HPV-18 was 0.76%, and HPV non-16,18 was 2.7%. In patients ≤ 50 years, prevalence of HPV-16 was 0.97%, HPV-18 was 0.38%, and HR-HPV non-16,18 was 2.71%. In patients > 50 years, prevalence of HPV-16 was 2.89%, HPV-18 was 2.17%, and HR-HPV non-16,18 was 2.89%. The difference in the prevalence of HPV-16,18 between patients ≤ and > 50 years was found to be highly statistically significant ( = 0.007485). The difference in the prevalence of total HR-HPV between patients ≤ and > 50 years was not found to be statistically significant ( = 0.059905).

Conclusion: Our study's finding of higher HR-HPV positivity rates in patients > 50 years emphasizes the need for continued HR-HPV-DNA-based screening of this cohort. With widespread use in post-menopausal patients, HPV screening can serve as an important armamentarium in the fight against cervical cancer.

References

Gravitt P, Rositch A, Silver M, Marks M, Chang K, Burke A . A cohort effect of the sexual revolution may be masking an increase in human papillomavirus detection at menopause in the United States. J Infect Dis. 2012; 207(2):272-80. PMC: 3532829. DOI: 10.1093/infdis/jis660. View

Vinodhini K, Shanmughapriya S, Sanmugham S, Senthikumar G, Das B, Natarajaseenivasan K . Prevalence of high-risk HPV and associated risk factors in cases of cervical carcinoma in Tamil Nadu, India. Int J Gynaecol Obstet. 2012; 119(3):253-6. DOI: 10.1016/j.ijgo.2012.06.019. View

Aggarwal R, Gupta S, Nijhawan R, Suri V, Kaur A, Bhasin V . Prevalence of high--risk human papillomavirus infections in women with benign cervical cytology: a hospital based study from North India. Indian J Cancer. 2006; 43(3):110-6. DOI: 10.4103/0019-509x.27932. View

Rajaram S, Gupta B . Screening for cervical cancer: Choices & dilemmas. Indian J Med Res. 2021; 154(2):210-220. PMC: 9131755. DOI: 10.4103/ijmr.IJMR_857_20. View

Brown D, Weaver B . Human papillomavirus in older women: new infection or reactivation?. J Infect Dis. 2012; 207(2):211-2. PMC: 3532821. DOI: 10.1093/infdis/jis662. View

Bruni L, Diaz M, Castellsague X, Ferrer E, Bosch F, de Sanjose S . Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis. 2010; 202(12):1789-99. DOI: 10.1086/657321. View

Nofech-Mozes S, Khalifa M, Ismiil N, Dube V, Saad R, Sun P . Detection of HPV-DNA by a PCR-based method in formalin-fixed, paraffin-embedded tissue from rare endocervical carcinoma types. Appl Immunohistochem Mol Morphol. 2009; 18(1):80-5. DOI: 10.1097/PAI.0b013e3181ae7240. View

Schiffman M, Castle P, Jeronimo J, Rodriguez A, Wacholder S . Human papillomavirus and cervical cancer. Lancet. 2007; 370(9590):890-907. DOI: 10.1016/S0140-6736(07)61416-0. View

Moosa K, Alsayyad A, Quint W, Gopala K, DeAntonio R . An epidemiological study assessing the prevalence of human papillomavirus types in women in the Kingdom of Bahrain. BMC Cancer. 2014; 14:905. PMC: 4265506. DOI: 10.1186/1471-2407-14-905. View

10.

Ho G, Bierman R, Beardsley L, Chang C, Burk R . Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med. 1998; 338(7):423-8. DOI: 10.1056/NEJM199802123380703. View

11.

Gravitt P, Paul P, Katki H, Vendantham H, Ramakrishna G, Sudula M . Effectiveness of VIA, Pap, and HPV DNA testing in a cervical cancer screening program in a peri-urban community in Andhra Pradesh, India. PLoS One. 2010; 5(10):e13711. PMC: 2965656. DOI: 10.1371/journal.pone.0013711. View

12.

Winer R, Hughes J, Feng Q, Xi L, Cherne S, OReilly S . Early natural history of incident, type-specific human papillomavirus infections in newly sexually active young women. Cancer Epidemiol Biomarkers Prev. 2010; 20(4):699-707. PMC: 3078690. DOI: 10.1158/1055-9965.EPI-10-1108. View

13.

Dutta S, Begum R, Mazumder Indra D, Mandal S, Mondal R, Biswas J . Prevalence of human papillomavirus in women without cervical cancer: a population-based study in Eastern India. Int J Gynecol Pathol. 2012; 31(2):178-183. DOI: 10.1097/PGP.0b013e3182399391. View

14.

Bhatla N, Lal N, Bao Y, Ng T, Qiao Y . A meta-analysis of human papillomavirus type-distribution in women from South Asia: implications for vaccination. Vaccine. 2008; 26(23):2811-7. DOI: 10.1016/j.vaccine.2008.03.047. View

15.

Delere Y, Schuster M, Vartazarowa E, Hansel T, Hagemann I, Borchardt S . Cervicovaginal self-sampling is a reliable method for determination of prevalence of human papillomavirus genotypes in women aged 20 to 30 years. J Clin Microbiol. 2011; 49(10):3519-22. PMC: 3187348. DOI: 10.1128/JCM.01026-11. View

16.

Tang S, Liao Y, Hu Y, Shen H, Wan Y, Wu Y . HPV Prevalence and Genotype Distribution Among Women From Hengyang District of Hunan Province, China. Front Public Health. 2021; 9:710209. PMC: 8602211. DOI: 10.3389/fpubh.2021.710209. View